TPDB

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB92402

Peptide_Name

Z-2

Activity

Antibacterial Anticancer Toxicity iDPPIV

Activity_category_statistics

Anti-infective peptides Cardiometabolic peptides Cancer-related peptides Toxicity and safety peptides

Database_Source

Peptipedia CancerPPD 2.0 iDPPIV pep-lab

Sequence_Type

standard

Has_Modification No

Description A 5-aa standard natural multi-activity (Antibacterial, Anticancer, Toxicity, and other sources) peptide sequence curated from Peptipedia, CancerPPD 2.0, iDPPIV, and other sources, with an available 3D structural model.

Modification

C-terminal: Cyclized N-terminal: Cyclized

Sequence

LPLPL

FASTA

>TPDB92402|Antibacterial;Anticancer;Toxicity;iDPPIV|length=5
LPLPL

Formula C28H49N5O6

Absent Amino Acids ARNDCEQGHIKMFSTWYV

Common Amino Acids L

Mass 551.73

PI 6.02

Basic Residues 0

Acidic Residues 0

Hydrophobic Residues 3

Net Charge -0

Boman Index -0.78

Hydrophobicity 1.640

Aliphatic Index 234.00

Half Life

Mammalian: 5.5 hour Yeast: 3 min E.coli: 2 min

Extinction Coefficient Cystines 0

Absorbance 280nm 0.00

Polar Residues 0

number

0

A

0

R

0

N

0

D

0

C

0

E

0

Q

0

G

0

H

0

I

3

L

0

K

0

M

0

F

2

P

0

S

0

T

0

W

0

Y

0

V

Amino Acid Distribution

A: 0 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 3 K: 0 M: 0 F: 0 P: 2 S: 0 T: 0 W: 0 Y: 0 V: 0

Length

5

Formula

C28H49N5O6

Mass

551.73

PI

6.02

Net Charge

-0

Boman Index

-0.78

Hydrophobicity

1.640

C_terminal_Modification

Cyclized

Chirality

L

Linear_or_Cyclic

Cyclic

N_terminal_Modification

Cyclized

Nature

Anticancer

Origin

Synthetic

Evidence 1 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 4.68 ± 1.22 µg/ml

Detail Source Activity Anticancer

Activity Measurement 4.68

Target

Cancer Type Breast Cancer

Cell Line MCF-7

Tissue Affected Breast

Assay & Model

Assay MTT assay

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2022

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 11.95 ± 0.64 µg/ml

Detail Source Activity Anticancer

Activity Measurement 11.95

Target

Cancer Type Liver Cancer

Cell Line HepG-2

Tissue Affected Liver

Assay & Model

Assay MTT assay

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2022

Evidence 3 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 14.45 ± 1.1 µg/ml

Detail Source Activity Anticancer

Activity Measurement 14.45

Target

Cancer Type Breast Cancer

Cell Line MDA-MB-231

Tissue Affected Breast

Assay & Model

Assay MTT assay

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2022

Evidence 4 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 14.5 ± 0.36 µg/ml

Detail Source Activity Anticancer

Activity Measurement 14.5

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT assay

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2022

Evidence 5 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 7.97 ± 2.06 µg/ml

Detail Source Activity Anticancer

Activity Measurement 7.97

Target

Cancer Type Lung Cancer

Cell Line A-549

Tissue Affected Lung

Assay & Model

Assay MTT assay

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2022

Evidence 6 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 2.25 ± 0.42 µg/ml

Detail Source Activity Anticancer

Activity Measurement 2.25

Target

Cancer Type Breast Cancer

Cell Line MCF-7

Tissue Affected Breast

Assay & Model

Assay MTT assay

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2022